The clinical significance of CD10 antigen expression in diffuse large B-cell lymphoma.

Abstract

The clinical significance and prognostic value of CD10 in de novo diffuse large B-cell lymphoma (DLBCL) is largely unknown. We retrospectively studied 19 men and 9 women based on the following criteria: (1) DLBCL with no evidence of concomitant or antecedent follicular lymphoma; (2) available flow cytometric immunophenotyping data, including CD10 status; (3) older than 15 years; (4) specific exclusion of high-grade, Burkitt-like lymphoma; and (5) exclusion of primary cutaneous DLBCL. When available, clinical data at diagnosis, including components of the international prognostic index, were reviewed. Eleven cases were CD10+, and 17 were CD10-. There was no significant difference between the CD10+ and CD10- groups in age, sex, stage, performance status, extranodal involvement, or serum lactate dehydrogenase levels at diagnosis. However, in the 26 cases for which follow-up data were available, the CD10+ group displayed a shorter overall survival than the CD10- group (8 vs 30 months). Although the clinical findings at diagnosis are similar in CD10+ and CD10- DLBCL, CD10 expression is associated with shortened overall survival. Therefore, our data suggest CD10 expression may have prognostic importance in adults with de novo DLBCL.

• Authors: P Uherova, C W Ross, B Schnitzer, T P Singleton, W G Finn
• Journal: American journal of clinical pathology (Am J Clin Pathol) Vol. 115 Issue 4 Pg. 582-8 (Apr 2001) ISSN: 0002-9173 [Print] England
• PMID: 11293907 (Publication Type: Journal Article)

Chemical References

• Neprilysin

Topics

• Adult
• Aged
• Aged, 80 and over
• Cell Separation
• Female
• Flow Cytometry
• Humans
• Immunophenotyping
• Lymphoma, B-Cell (immunology, metabolism)
• Lymphoma, Large B-Cell, Diffuse (immunology, metabolism)
• Male
• Middle Aged
• Neprilysin (biosynthesis)
• Prognosis
• Retrospective Studies
• Survival Rate